Growth arrest of BCR-ABL positive cells with a sequence-specific polyamide-chlorambucil conjugate

PLoS ONE

Volumn 3, Issue 10, 2008, Pages

  Chou, C James ^a   O'Hare, Thomas ^b   Lefebvre, Sophie ^a   Alvarez, David ^a,c   Tyner, Jeffrey W ^b   Eide, Christopher A ^b   Druker, Brian J ^b   Gottesfeld, Joel M ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c KEAN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CHLORAMBUCIL; IMATINIB; IMIDAZOLE; POLYAMIDE; PYRROLE; ALKYLATING AGENT; NYLON; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOTOXICITY; DNA SEQUENCE; DOSE RESPONSE; DRUG CONJUGATION; DRUG FORMULATION; DRUG TOLERABILITY; GROWTH INHIBITION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; SINGLE DRUG DOSE; TOXICITY TESTING; TUMOR XENOGRAFT; ANIMAL; BIOLOGICAL MODEL; BLOOD CELL; BONE MARROW CELL; CELL CULTURE; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECT; DRUG SCREENING; ENZYME SPECIFICITY; GENETIC TRANSDUCTION; GENETICS; METABOLISM; NUCLEOTIDE SEQUENCE; PATHOLOGY; PHYSIOLOGY;

MURINAE;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; BASE SEQUENCE; BLOOD CELLS; BONE MARROW CELLS; CELL PROLIFERATION; CELLS, CULTURED; CHLORAMBUCIL; DRUG EVALUATION, PRECLINICAL; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MICE; MODELS, BIOLOGICAL; NYLONS; PIPERAZINES; PYRIMIDINES; SUBSTRATE SPECIFICITY; TRANSDUCTION, GENETIC;

EID: 56349171403     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0003593     Document Type: Article

References (33)

1. Rowley JD (1973) Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243: 290-293.
2. Sawyers CL (1999) Chronic myeloid leukemia. N Engl J Med 340: 1330-1340.
3. Deininger MW, Vieira S, Mendiola R, Schultheis B, Goldman JM, et al. (2000) BCR-ABL tyrosine kinase activity regulates the expression of multiple genes implicated in the pathogenesis of chronic myeloid leukemia. Cancer Res 60: 2049-2055.
4. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, et al. (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2: 561-566.
5. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, et al. (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355: 2408-2417.
6. O'Hare T, Eide CA, Deininger MW (2007) Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 110: 2242-2249.
7. Ottmann OG, Druker BJ, Sawyers CL, Goldman JM, Reiffers J, et al. (2002) A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 100: 1965-1971.
8. Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, et al. (2002) Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 99: 3530-3539.
9. Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passerini C, et al. (2002) Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 99: 1928-1937.
10. Shah NP, Tran C, Lee FY, Chen P, Norris D, et al. (2004) Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305: 399-401.
11. O'Hare T, Walters DK, Stoffregen EP, Jia T, Manley PW, et al. (2005) In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 65: 4500-4505.
12. Robak T, Kasznicki M (2002) Alkylating agents and nucleoside analogues in the treatment of B cell chronic lymphocytic leukemia. Leukemia 16: 1015-1027.
13. Nicolle A, Proctor SJ, Summerfield GP (2004) High dose chlorambucil in the treatment of lymphoid malignancies. Leuk Lymphoma 45: 271-275.
14. Brooks N, Hartley JA, Simpson JE Jr, Wright SR, Woo S, et al. (1997) Structure-activity relationship of a series of C-terminus modified aminoalkyl, diaminoalkyl-and anilino-containing analogues of the benzoic acid mustard distamycin derivative tallimustine: synthesis, DNA binding and cytotoxicity studies. Bioorg Med Chem 5: 1497-1507.
15. Urbaniak MD, Bingham JP, Hartley JA, Woolfson DN, Caddick S (2004) Design and synthesis of a nitrogen mustard derivative stabilized by apo-neocarzinostatin. J Med Chem 47: 4710-4715.
16. Wurtz NR, Dervan PB (2000) Sequence specific alkylation of DNA by hairpin pyrrole-imidazole polyamide conjugates. Chem Biol 7: 153-161.
17. Oyoshi T, Kawakami W, Narita A, Bando T, Sugiyama H (2003) Inhibition of transcription at a coding sequence by alkylating polyamide. J Am Chem Soc 125: 4752-4754.
18. Shinohara K, Narita A, Oyoshi T, Bando T, Teraoka H, et al. (2004) Sequence-specific gene silencing in mammalian cells by alkylating pyrrole-imidazole polyamides. J Am Chem Soc 126: 5113-5118.
19. Dickinson LA, Burnett R, Melander C, Edelson BS, Arora PS, et al. (2004) Arresting cancer proliferation by small-molecule gene regulation. Chem Biol 11: 1583-1594.
20. Chou CJ, Farkas ME, Tsai SM, Alvarez D, Dervan PB, et al. (2008) Small molecules targeting histone H4 as potential therapeutics for chronic myelogenous leukemia. Mol Cancer Ther 7: 769-778.
21. Tsai SM, Farkas ME, Chou CJ, Gottesfeld JM, Dervan PB (2007) Unanticipated differences between {alpha}- and {gamma}-diaminobutyric acid-linked hairpin polyamide-alkylator conjugates. Nucleic Acids Res 35: 307-316.
22. Farkas ME, Tsai SM, Dervan PB (2007) alpha-Diaminobutyric acid-linked hairpin polyamides. Bioorg Med Chem 15: 6927-6936.
23. Alvarez D, Chou CJ, Latella L, Zeitlin SG, Ku S, et al. (2006) A two-hit mechanism for pre-mitotic arrest of cancer cell proliferation by a polyamide-alkylator conjugate. Cell Cycle 5: 1537-1548.
24. Weiss GR, Poggesi I, Rocchetti M, DeMaria D, Mooneyham T, et al. (1998) A phase I and pharmacokinetic study of tallimustine [PNU 152241 (FCE 24517)] in patients with advanced cancer. Clin Cancer Res 4: 53-59.
25. Lockhart AC, Howard M, Hande KR, Roth BJ, Berlin JD, et al. (2004) A phase I dose-escalation and pharmacokinetic study of brostallicin (PNU-166196A), a novel DNA minor groove binder, in adult patients with advanced solid tumors. Clin Cancer Res 10: 468-475.
26. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, et al. (2001) Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344: 1038-1042.
27. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, et al. (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344: 1031-1037.
28. Jahagirdar BN, Miller JS, Shet A, Verfaillie CM (2001) Novel therapies for chronic myelogenous leukemia. Exp Hematol 29: 543-556.
29. Capdeville R, Buchdunger E, Zimmermann J, Matter A (2002) Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 1: 493-502.
30. von Bubnoff N, Peschel C, Duyster J (2003) Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back. Leukemia 17: 829-838.
31. Nimmanapalli R, Bhalla K (2002) Mechanisms of resistance to imatinib mesylate in Bcr-Abl-positive leukemias. Curr Opin Oncol 14: 616-620.
32. Olivieri A, Manzione L (2007) Dasatinib: a new step in molecular target therapy. Ann Oncol 18(Suppl 6): vi42-46.
33. O'Hare T, Eide CA, Tyner JW, Corbin AS, Wong MJ, et al. (2008) SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinib. Proc Natl Acad Sci U S A 105: 5507-5512.